Penicillin G potassium, non-sterile

Nystatin powder

Centrient Pharmaceuticals provides wide range of anti-fungals which includes nystatin powder. Characteristics: a crystalline powder. Application: the product is suitable among others for the manufacture of creams, ointments, tablets and vaginal tablets after the addition of the appropriate excipients....

Oxacillin sodium compacted

Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes oxacillin sodium compacted. Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Application: the product is suitable for the manufacture of capsules ...

Penicillin G potassium, non-sterile

Cntrient Pharmaceuticals provides wide range of penicillin products which includes penicillin g potassium, non-sterile. Characteristics: a crystalline powder. Application: this product is suitable as a starting material for the manufacture of sterile penicillin g salts and the manufacture of beta- lac...

Centrient Pharmaceuticals provides wide range of penicillin products which includes penicillin g potassium, non-sterile. Characteristics: a crystalline powder. Application: this product is suitable as a starting material for the manufacture of sterile penicillin g salts and the manufacture of beta- lactam ...

Penicillin G procaine

Centrient Pharmaceuticals provides wide range of penicillin products which includes penicillin g procaine. Characteristics: a crystalline powder. Application: this product is suitable as medicated feed additive for veterinary use. Therapeutic category: narrow spectrum antibiotic. Contact us for more inform...

Penicillin V

Centrient Pharmaceuticals provides wide range of drug products which includes penicillin v. Dosage form: film-coated tablets. Contact us for more information.

Puricillin® Compacted (ampicillin trihydrate)

Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

Available Marketing Authorizations 

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics. Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range.

Centrient Pharmaceuticals is a business-to-business provider of generics FDFs, not marketing the products ourselves. Therefore, we do not compete with our customers in the end market. All our dossiers are readily available for out-licensing to our partners worldwide. We work primarily with Europe-based FDFs manufacturers. Customers can be confident that the origin, traceability, and quality of our products are impeccable. We offer a dual sourcing strategy and procurement excellence for our third-party-produced APIs.

With our innovative enzymatic platform, we've been changing the game for sustainable antibiotics and statins production, step by step.

We are a leading business-to-business provider of generic APIs. We help to secure patient safety, by driving Quality to the next level. Our reputation for producing high-quality generic APIs is well-known throughout the industry. Additionally, our business-to-business customers using our enzymatically produced APIs enjoy the freedom to operate, as these technologies are protected by patents.

Doubling our API capacity to meet the growing demand

Achieving a PNEC-compliant supply chain

Sustainability matters a great deal to everyone at Centrient Pharmaceuticals, it is core to our mission and essential in shaping our authentic and purposeful culture. Our ESG Ambition means that we not only ‘do what we say,’ but also we are eager to share the significant progress we are making and demonstrate our strong industry leadership position by ‘saying what we do.’ We are proud to share our latest ESG Report 2021 summing up our accomplishments as a company.